Marianna Spatola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Marianna Spatola has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Thierry Kuntzer
CHU Vaudois and University of Lausanne; Nerve-Muscle Unit, Service of Neurology; Lausanne Switzerland 1011
2 shared publications - Alexandre Croquelois
Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland
1 shared publication - Andrea O. Rossetti
Department of Clinical Neurosciences, Neurology Service, University Hospital (CHUV) and Faculty of Biology and Medicine of Lausanne, Switzerland
1 shared publication Bernard Nater
1 shared publicationChristian Wider
1 shared publication- Christian Wider
From the Service of Neurology, Department of Clinical Neurosciences (C.W.), and Neuroscience Research Center (CRN) (C.W.), Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UNIL), Switzerland; and the Center for Neurodegenerative and Neuroimmunologic Diseases (M.M.M.), Department of Neurology, Rutgers Biomedical and Health Sciences, Robert Wood Johnson Medical School, Piscataway, NJ.
1 shared publication
Latest Publications
- Open Access
- 16 April 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-4
PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain
LEOPARD syndrome (LS) belongs to the family of neuro-cardio-facio-cutaneous syndromes, which include Neurofibromatosis-1 (NF1), Noonan syndrome, Costello Syndrome, cardio-facio-cutaneous syndrome, Noonan-like syndrome with loose anagen hair and Legius syndrome. These conditions are caused by mutations in genes encoding proteins involved in the RAS-MAPK cellular pathway. Clinical heterogeneity and phenotype overlaps across those different syndromes is already recognized. We hereby report a heterozygous de novo mutation in the PTPN11 gene (c.1403C > T) manifesting with a clinical picture of LS during childhood, and later development of neuropathic pain with hypertrophic plexi, which are typically observed in NF1 but have not been reported in LS. LS caused by PTPN11 mutations may be associated with hypertrophic roots and plexi. Consequently, clinicians should be aware of the possible development of neuropathic pain and consider specific diagnostic work-up and management.
- 16 April 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-4
Open AccessPTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain
LEOPARD syndrome (LS) belongs to the family of neuro-cardio-facio-cutaneous syndromes, which include Neurofibromatosis-1 (NF1), Noonan syndrome, Costello Syndrome, cardio-facio-cutaneous syndrome, Noonan-like syndrome with loose anagen hair and Legius syndrome. These conditions are caused by mutations in genes encoding proteins involved in the RAS-MAPK cellular pathway. Clinical heterogeneity and phenotype overlaps across those different syndromes is already recognized. We hereby report a heterozygous de novo mutation in the PTPN11 gene (c.1403C > T) manifesting with a clinical picture of LS during childhood, and later development of neuropathic pain with hypertrophic plexi, which are typically observed in NF1 but have not been reported in LS. LS caused by PTPN11 mutations may be associated with hypertrophic roots and plexi. Consequently, clinicians should be aware of the possible development of neuropathic pain and consider specific diagnostic work-up and management.
- 15 January 2014
- Vol. 10, 78-81
[News in neurology 2013].
In 2013, perampanel is approved as an add-on treatment for generalised and focal seizures in pharmaco-resistant epilepsy. New anticoagulants are superior to antivitamin K in stroke secondary prevention in case of atrial fibrillation. DBS remains a valid therapeutic option for advanced Parkinson's disease. Intranasal ketamine seems to reduce the intensity of severe migraine aura. High concentrations of topic capsaicin improve post-herpetic neuralgia. In Alzheimer's disease, statins might deteriorate cognitive functions. Oral immuno-modifing treatments for relapsing remitting multiple sclerosis have shown to slow cerebral atrophy progression at two years.
- 15 January 2014
- Vol. 10, 78-81
[News in neurology 2013].
In 2013, perampanel is approved as an add-on treatment for generalised and focal seizures in pharmaco-resistant epilepsy. New anticoagulants are superior to antivitamin K in stroke secondary prevention in case of atrial fibrillation. DBS remains a valid therapeutic option for advanced Parkinson's disease. Intranasal ketamine seems to reduce the intensity of severe migraine aura. High concentrations of topic capsaicin improve post-herpetic neuralgia. In Alzheimer's disease, statins might deteriorate cognitive functions. Oral immuno-modifing treatments for relapsing remitting multiple sclerosis have shown to slow cerebral atrophy progression at two years.
- 31 January 2012
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 18, S158-S161
Overview of primary monogenic dystonia
- 31 January 2012
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 18, S158-S161
Overview of primary monogenic dystonia